JUNSHI BIO

Junshi Biosciences opened lower and extended losses in the afternoon session, closing at HKD 18.41, down 5.0% from the prior close of 19.38, with an intraday range of approximately 5.4%, mainly driven by profit-taking after a recent strong rally. The stock briefly recovered to 19.41 after an early morning low of 18.50 but lacked support in the afternoon, sliding to the day's low of 18.41. On the news front, the company completed a RMB 300 million technology innovation bond issuance and received NMPA acceptance for Toripalimab plus chemotherapy as perioperative treatment for resectable stage II-III NSCLC, while the market focused on a previously disclosed shareholder reduction plan and low daily turnover of HKD 19.1 million. Financially, Q1 revenue rose 53.6% YoY and net loss narrowed sharply by 90.7%, showing clear fundamental improvement, yet the current price of 18.41 remains below the 20-day MA of 18.65 and 60-day MA of 20.14, with a YTD decline of 17.4% and a 52.4% discount from the 52-week high of 38.64, indicating a stretched valuation but short-term momentum is weak.

Shanghai Junshi Biosciences opened higher and fluctuated in the morning session. After initially dipping to a low of HKD 17.96, the stock rebounded to close at HKD 18.80, up 6.58% from the previous close of HKD 17.64, with an intraday high of HKD 18.92. The rally was primarily driven by a licensing agreement with Fosun Wanbang for the IL-17A antibody Roconkibart (JS005) in Greater China, securing an upfront payment of CNY 215 million, along with the company's call for an EGM to seek H-share buyback authorization. Financially, Q1 2026 revenue reached HKD 823 million (+53.59% YoY), while net loss narrowed sharply to HKD 23.3 million (+90.73% YoY). Technically, the stock is trading above its 20-day MA of HKD 18.061 but below the 60-day MA of HKD 20.621, with a year-to-date decline of 15.62% and a 51.35% drawdown from the 52-week high of HKD 38.64. However, a major shareholder has disclosed a plan to reduce its stake.

Junshi Biosciences opened lower and extended losses in the morning session, closing at HK$19.13, down approximately 5.0% from the prior close. The stock fell from an intraday high of HK$20.14 to a low of HK$19.13, with total volume of about 582,800 shares. Despite yesterday's licensing agreement with Fosun Wanbang for IL-17A inhibitor JS005 in Greater China, which includes a CNY 215 million upfront payment, the stock declined, suggesting market concerns over the pace of deal execution. Recent disclosure of a stake reduction by a major shareholder group also weighed on sentiment. The stock is now 50.5% below its 52-week high of HK$38.64 and down 14.1% year-to-date, while trading below both its 20-day MA (HK$18.02) and 60-day MA (HK$20.80), indicating a weak medium-term trend. However, the PB multiple stands at 2.94x, and the recent positive Phase 3 readout for toripalimab in perioperative NSCLC adds long-term pipeline support.

Junshi Biosciences shares surged and then pulled back, closing at HK$20.32, up 5.78% from the previous close of HK$19.21, with a daily range of 11.9%. Driven by the licensing agreement with Fosun Wanbang for the IL-17A monoclonal antibody JS005 in Greater China, which includes a RMB 215 million upfront payment, the stock rose to an intraday high of HK$21.50 in the morning session, but gradually declined in the afternoon. The closing price remains below the 60-day moving average of HK$21.105. The company's Q1 2026 operating revenue grew 53.59% YoY to HK$823 million, and net loss narrowed sharply by 90.73% to HK$23.31 million, reflecting improved fundamentals. However, the stock is still down 8.8% year-to-date and is 47.41% below its 52-week high of HK$38.64, suggesting profit-taking pressure from short-term buyers who entered near the 52-week low.

Junshi Biosciences opened higher and extended gains in the morning session, rising over 5% to touch HKD 19.52 by 10:03 BJ, up 5.06% from the previous close of HKD 18.58. The move was driven by the signing of an exclusive license agreement with Fosun Wanbang for IL-17A antibody JS005 (Roconkibart) in Greater China, with an upfront payment of RMB 215 million. Adding to the bullish sentiment, the company also called an EGM to seek a mandate for H-share buybacks and disclosed that its chairman had completed a RMB 100 million shareholding increase. Financially, Q1 2026 revenue rose 53.59% YoY to HKD 823 million, while net loss narrowed sharply by 90.73% to HKD 23.3 million, with net profit margin improving to -2.83% from -40.35% a year ago. Despite the strong fundamental improvement, the current price of HKD 19.52 remains 49.48% below the 52-week high of HKD 38.64 and trades below the 60-day moving average of HKD 21.47, with the stock still down 12.39% year-to-date from HKD 22.28.